Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer

NCT ID: NCT02978222

Last Updated: 2022-12-15

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 120 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-07-20
• Study Completion Date: 2020-01-15

Brief Summary

This is a double-blind, randomized, parallel groups Phase II trial. Patients with platinum-sensitive advanced ovarian cancer, defined as a lack of progression by RECIST v1.1 criteria following completion of standard-of-care chemotherapy, including a minimum of 4 cycles of a platinum-containing regimen. Patients will be randomized to either the vaccine regimen with GM-CSF adjuvant or GM-CSF adjuvant alone as a control group. Treatment will be administered as a consolidation therapy within one year of the last administration of platinum, targeting the first remission.

Detailed Description

This is a multicenter double-blind controlled randomized Phase II study to evaluate the activity of folate receptor alpha (FRα) peptide vaccine as a consolidation treatment following completion of no less than 4 cycles of a platinum containing regimen in patients with platinum-sensitive, non-mucinous ovarian, fallopian tube or primary peritoneal cancer.

The patients will have demonstrated a tumor response or stable disease upon their last regimen (per RECIST v1.1 and/or CA125 GCIG criteria) prior to enrolment in this study.

Following randomization, patients will be administered TPIV200 with GM-CSF adjuvant or GM-CSF control alone. Patients will have booster doses and tumor assessments done every 12 weeks ± 1 week for up to 1.5 years, until objective disease progression or the patient withdraws consent. Tumor responses will be assessed at the study sites by evaluating tumor images/scans according to RECIST v1.1.

Conditions

Platinum Sensitive Ovarian Cancer; Ovarian Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

FRα peptide plus adjuvant (GM-CSF)

FRα peptide vaccine with GM-CSF adjuvant ID administration monthly for 6 months followed by booster administrations every 3 months for up to 1.5 years

Group Type: EXPERIMENTAL

FRα peptide plus Adjuvant (GM-CSF)

Intervention Type: BIOLOGICAL

Intradermal injection FRα peptides, 500μg each - plus GM-CSF 125 μg

Adjuvant (GM-CSF) Alone

GM-CSF adjuvant alone ID administration monthly for 6 months followed by booster administrations every 3 months for up to 1.5 years

Group Type: PLACEBO_COMPARATOR

Adjuvant (GM-CSF) Alone

Intervention Type: DRUG

Intradermal injection 125 μg GM-CSF

Interventions

FRα peptide plus Adjuvant (GM-CSF)

Intradermal injection FRα peptides, 500μg each - plus GM-CSF 125 μg

Intervention Type: BIOLOGICAL

Adjuvant (GM-CSF) Alone

Intradermal injection 125 μg GM-CSF

Intervention Type: DRUG

Other Intervention Names

TPIV200 with GM-CSF adjuvant; Leukine®

Eligibility Criteria

Inclusion Criteria

1. Female patient ≥ 18 years

2. Willing and able to give informed consent

3. Stage III-IV platinum-sensitive (defined as a lack of progression by RECIST v1.1 criteria following completion of standard-of-care chemotherapy, including a minimum of 4 cycles of a platinum-containing regimen) epithelial ovarian, fallopian tube or primary peritoneal carcinoma in first remission.

4. Histologic documentation of diagnosis of carcinoma is required and the following histologic subtypes are eligible: high grade (grade ≥3+) serous or endometrioid carcinoma, carcinosarcoma, or poorly-differentiated adenocarcinoma, or mixed (including above subtypes only). Note that synchronous serous or endometrioid uterine or fallopian cancers are allowed.

5. The patient must have demonstrated an objective response (PR or CR) or stable disease (SD) with the last chemotherapy prior to enrollment and this response must be stable (without progressive disease) before randomization.

6. Patients must receive their first dose of vaccine within 1 year of completion of their final dose of a chemotherapeutic agent of the platinum-containing regimen

7. Adequate normal organ and marrow function within 14 days prior to first vaccine administration:

• Absolute neutrophil count > 1.5 x 109/L
• Platelet > 100 x 109/L
• Hemoglobin > 9.0 g/dL
• Serum bilirubin < 1.5 times ULN (unless Gilbert's syndrome without concurrent clinically significant liver disease
• AST/ALT < 2.5 ULN unless liver metastasis in which case it must be < 5 x ULN
• Serum creatinine CL > 40 mL/min by Cockcroft-Gault formula.

8. Anti-nuclear antibody (ANA) negative or low-positive institutional range, as determined within 28 days from registration. Intermediate values (usually defined by a titer of ≤1:80, or as indicated by institutional range) are acceptable if there are, in the opinion of the Investigator, no early signs of an autoimmune disease.

9. Female subjects must either be of non-reproductive potential (i.e. post-menopause by history: > 60 years old and no menses for > 12 months naturally or secondary to radiation/chemotherapy; OR serum FSH, LH and estradiol levels in the post-menopausal range; OR history of hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy), or must have a negative serum pregnancy test upon study entry

10. Life expectancy > 24 weeks

11. ECOG performance status of 0 or 1

12. Formalin fixed, paraffin embedded tumor sample from the primary cancer must be sent for central testing.

Criteria for Exclusion

1. Histology consistent with non-serous, non-endometrioid (i.e. mucinous or clear cell), or low-grade or borderline serous ovarian carcinoma

2. Patients with a history of other cancers (other than non-melanoma skin cancers [i.e. basal or squamous cell]) within the past 3 years.

3. Receipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy, targeted therapy, biological/cell therapy, tumor embolization, monoclonal antibodies, other investigational agent) < 28 days prior to the first dose of study drug.

4. Current or prior use of immunosuppressive medication within 28 days prior to the fist dose of study drug with the exception of topical, intranasal or inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid.

5. Active autoimmune disease requiring therapy within the past 2 years. Note: patients with vitiligo, Grave's disease or psoriasis not requiring systemic treatment within the past 2 years are not excluded.

6. History of hypersensitivity to GM-CSF

7. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses including any subject known to have evidence of acute or chronic hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent

8. Symptomatic thyroid disease, unless negative for thyroid antibodies (TSH receptor, TPO, thyroglobulin).

9. Subjects who are pregnant or are breast feeding.

10. Subjects who or of reproductive potential, and are either:

• Not abstinent;
• Not in an exclusive relationship with a partner who is surgically sterile;
• Not employing an effective method of birth control.

11. Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results

12. Symptomatic or uncontrolled brain metastasis requiring concurrent treatment, inclusive of but not limited to surgery, radiation and/or corticosteroids

13. Subject with uncontrolled seizures

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Marker Therapeutics, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Richard Kenney, MD

Role: STUDY_DIRECTOR

Marker Therapeutics, Inc.

Locations

UAB Gynecology Oncology

Birmingham, Alabama, United States

Mayo Clinic Cancer Center

Phoenix, Arizona, United States

Women's Cancer Research Foundation

Newport Beach, California, United States

The Stamford Hospital/Bennett Cancer Center

Stamford, Connecticut, United States

Mayo Clinic Florida

Jacksonville, Florida, United States

Mt. Sinai Comprehensive Cancer Center

Miami Beach, Florida, United States

Moffitt Cancer Center

Tampa, Florida, United States

Florida Cancer Specialist

West Palm Beach, Florida, United States

Mayo Clinic Rochester

Rochester, Minnesota, United States

Research Partners

Jackson, Mississippi, United States

MidAmerica Division, Inc. c/o Research Medical Center

Kansas City, Missouri, United States

University Of New Mexico Comprehensive Cancer Center

Albuquerque, New Mexico, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Hematology/Oncology Lenox Hill Hospital

New York, New York, United States

Duke University Medical Center

Durham, North Carolina, United States

OHSU

Portland, Oregon, United States

Abington Memorial Hospital

Abington, Pennsylvania, United States

Tennessee Oncology/Sarah Cannon Research Institute

Nashville, Tennessee, United States

Countries

United States

References

Gupta A, O'Cearbhaill RE, Block MS, Hamilton E, Konner JA, Knutson KL, Potts J, Garrett G, Kenney RT, Wenham RM; TPIV200 Ovarian Cancer Study Investigators (listed at the end). Vaccination with folate receptor-alpha peptides in patients with ovarian cancer following response to platinum-based therapy: A randomized, multicenter clinical trial. Gynecol Oncol. 2024 Oct;189:90-97. doi: 10.1016/j.ygyno.2024.07.675. Epub 2024 Jul 27.

Reference Type: DERIVED

PMID: 39068739 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

FRV-004

Identifier Type: -

Identifier Source: org_study_id